Sakar Healthcare Intrinsic Value
SAKAR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹178.64 | ₹142.91 - ₹214.37 | -53.0% | EPS: ₹8.12, Sector P/E: 22x |
| Book Value Method | asset | ₹260.00 | ₹234.00 - ₹286.00 | -31.6% | Book Value/Share: ₹130.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹214.55 | ₹193.10 - ₹236.01 | -43.6% | Revenue/Share: ₹107.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹223.57 | ₹201.21 - ₹245.93 | -41.2% | EBITDA: ₹52.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹209.92 | ₹167.94 - ₹251.90 | -44.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹114.03 | ₹102.63 - ₹125.43 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹125.45 | ₹112.91 - ₹138.00 | -67.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹190.05 | ₹171.05 - ₹209.06 | -50.0% | ROE: 7.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹154.11 | ₹138.70 - ₹169.52 | -59.5% | EPS: ₹8.12, BVPS: ₹130.00 |
Want to compare with current market value? Check SAKAR share price latest .
Valuation Comparison Chart
SAKAR Intrinsic Value Analysis
What is the intrinsic value of SAKAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sakar Healthcare (SAKAR) is ₹190.05 (median value). With the current market price of ₹380.10, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹114.03 to ₹260.00, indicating ₹114.03 - ₹260.00.
Is SAKAR undervalued or overvalued?
Based on our multi-method analysis, Sakar Healthcare (SAKAR) appears to be trading above calculated value by approximately 50.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.33 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.45 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 7.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Sakar Healthcare
Additional stock information and data for SAKAR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹34 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹25 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹33 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹36 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹15 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |